Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 35% Improvement Relative Risk HCQ for COVID-19  Guglielmetti et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 218 patients in Italy Lower mortality with HCQ (not stat. sig., p=0.22) c19hcq.org Guglielmetti et al., J. Infection and .., Dec 2020 Favors HCQ Favors control

Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave

Guglielmetti et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.11.012
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
Retrospective 218 hospitalized patients in Italy showing non-statistically significant 35% lower mortality with HCQ, hazard ratio aHR 0.65 [0.33–1.30].
risk of death, 35.0% lower, RR 0.65, p = 0.22, treatment 181, control 37, adjusted per study, multivariable Cox.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guglielmetti et al., 9 Dec 2020, retrospective, Italy, peer-reviewed, 16 authors, average treatment delay 8.0 days.
This PaperHCQAll
Severe COVID-19 pneumonia in Piacenza, Italy — A cohort study of the first pandemic wave
Lorenzo Guglielmetti, Irina Kontsevaya, Maria C Leoni, Patrizia Ferrante, Elisa Fronti, Laura Gerna, Caterina Valdatta, Alessandra Donisi, Alberto Faggi, Franco Paolillo, Giovanna Ratti, Alessandro Ruggieri, Marta Scotti, Daria Sacchini, Gloria Taliani, Mauro Codeluppi
Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.11.012
Background: Piacenza is the closest city to the first coronavirus disease 2019 (COVID-19) cluster in Italy and has the highest national COVID-19 death rates per population. The objective of this study is to present characteristics and outcomes of patients admitted to medical departments of the Hospital of Piacenza during the first wave of the epidemic. Methods: A total of 218 patients with confirmed or suspect COVID-19 and severe pneumonia were included from February 21st to May 15th, 2020. Routinely-collected clinical and laboratory data were retrospectively retrieved from electronic medical files. A Cox proportional-hazards model was fit to assess the association of treatment and other variables with death. Results: Median age of patients was 68 years; 150 patients (69%) had comorbidities, mainly hypertension (107, 49%). Overall, 185 (85%) patients had acute respiratory distress syndrome (ARDS) on admission, including 103 (47%) with moderate or severe ARDS. Chest computed tomography scan showed bilateral disease in 201 (98%) and extensive lung involvement in 79 (50%) patients. Most patients received antiviral treatment (187, 86%) and corticosteroids (134, 61%). All patients received respiratory support and 64 (29%) were admitted to intensive care unit. As of June 30th, 100 patients (46%) died, 109 patients (50%) were discharged, and 9 patients (4%) were still hospitalized. In multivariable Cox analysis, age above 65 years, having more than one comorbidity, severe ARDS, low platelet counts, and high LDH levels at admission were associated with mortality, while having diarrhea at admission was associated with survival. The use of antivirals or corticosteroids was not associated with survival.
Competing interests None declared. Ethics approval The study was approved by the local Ethics Committee (Area Vasta Emilia Nord). Requirement for informed consent was waived by the Ethics Committee. Author contributions LG made a substantial contribution to the conception and design of the work, to the acquisition, analysis and interpretation of data for the work, performed statistical analysis, wrote the manuscript, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. IK made a substantial contribution to the analysis and interpretation of data for the work, wrote the manuscript, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. GT and MC made a substantial contribution to the conception and design of the work, to the analysis and interpretation of data for the work, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agree to be accountable for all aspects of the..
References
Arabi, Mandourah, Al-Hameed, Sindi, Almekhlafi et al., Corticosteroid therapy for critically ill patients with middle east respiratory syndrome, Am J Respir Crit Care Med, doi:10.1164/rccm.202004-1153ED
Arentz, Yim, Klaff, Lokhandwala, Riedo et al., Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State, JAMA, doi:10.1056/NEJMoa2002032
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med, doi:10.1001/jama.2020.17023
Berté, Cassinelli, Vignola, Bonfanti, Pagano et al., be adapted to manage this "ultra-emergency
Bhatraju, Ghassemieh, Nichols, Kim, Jerome et al., Covid-19 in critically ill patients in the Seattle Region -case series, N Engl J Med, doi:10.1001/jama.2020.4326
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282.NEJMoa2001282
Chen, Wu, Chen, Yang, Chen, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, doi:10.1001/jamainternmed.2020.0994
Chen, Zheng, Zhang, Zhang, Wu et al., Clinical characteristics of 145 patients with corona virus disease, doi:10.1164/rccm.202003-0736LE
Cheng, Shan, Novel coronavirus: where we are and what we know, Infection, doi:10.1007/s15010-020-01401-y
Colombi, Bodini, Petrini, Maffi, Morelli et al., Well-aerated lung on admitting chest CT to predict adverse outcome in COVID-19 pneumonia, Radiology, doi:10.1148/radiol.2020201433
Fagiuoli, Lorini, Remuzzi, Adaptations and lessons in the province of Bergamo, N Engl J Med, doi:10.1007/s15010-020-01436-1
Ferrari, Gerardi, Manzi, Micheletti, Nicolussi et al., COVID-19 in Italy: an app for a province-based analysis
Fusaroli, Balena, Lisotti, On the death of 100 + Italian doctors from COVID-19, Infection, doi:10.1007/s15010-020-01420-9
Grasselli, Pesenti, Cecconi, Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response, JAMA, doi:10.1007/s15010-020-01440-5
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA, doi:10.1001/jama.2020.4031
Group Twrea For C-19, React) W, Sterne, Murthy, Diaz et al., Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA, doi:10.1164/rccm.201706-1172OC
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032.NEJMoa2002032
Guglielmetti, Chiesi, COVID-19 in Italy: passing through bitter waters, Eur Respir J, doi:10.1183/13993003.01812-2020
Hermine, Mariette, Tharaux, Resche-Rigon, Porcher et al., Effect of Tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial, JAMA Intern Med, doi:10.1056/NEJMoa2007764
Horby, Mafham, Bell, Linsell, Staplin et al., Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, doi:10.1056/NEJMoa2001282
Horby, Mafham, Linsell, Bell, Staplin et al., Effect of Hydroxychloroquine in hospitalized Patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial, MedRxiv, doi:10.1016/S0140-6736(20)32013-4
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1056/NEJMoa2004500
Li, Romagnani, Von Brunn, Anders, SARS-CoV-2 and Europe: timing of containment measures for outbreak control, Infection, doi:10.1183/13993003.01812-2020
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA, doi:10.1016/S0140-6736(20)30183-5
Section, Vademecum for the treatment of people with COVID-19. Edition 2.0, 13, Infez Med
Setti, Passarini, Gennaro, Baribieri, Perrone, SARS-cov-2 RNA found on particulate matter of Bergamo in Northern Italy: first preliminary evidence, Infect Dis (Except HIV/AIDS, doi:10.1001/jamanetworkopen.2020.5619
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-Infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.6775
Wang, Lu, Chen, Chen, Su et al., Clinical course and outcomes of 344 intensive care patients with COVID-19, Am J Respir Crit Care Med, doi:10.1001/jama.2020.1585
Waterer, Rello, Wunderink, SARS-CoV-2: first do No harm, Am J Respir Crit Care Med, doi:10.1101/2020.07.15.20151852
Who, Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected
Who, Global surveillance for COVID-19 caused by human infection with COVID-19 virus, doi:10.1001/jama.2020.5394
Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jama.2020.3204
Wunsch, Mechanical ventilation in COVID-19: interpreting the current epidemiology, Am J Respir Crit Care Med, doi:10.1001/jamainternmed.2020.6820
Xie, Tong, Guan, Du, Qiu, Clinical characteristics of patients who died of coronavirus disease 2019 in China, JAMA Netw Open, doi:10.1164/rccm.202004-1385ED
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/S0140-6736(20)30566-3
Young, Ong, Kalimuddin, Low, Tan et al., Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore, JAMA, doi:10.1001/jama.2020.3204
Zhang, Shang, Liu, Zhang, Zheng et al., Clinical characteristics of 194 cases of COVID-19 in Huanggang and Taian, Infection, doi:10.1007/s15010-020-01440-5
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1148/radiol.2020201433
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit